Hepatic artery chemoembolization (TACE) is mainly applied to unresectable hepatocellular carcinoma, especially those with predominantly right lobe or multiple foci, or those who cannot be surgically resected due to postoperative recurrence. For liver cancer that cannot be radically resected after several times of TACE treatment, if the tumor shrinks significantly, and although most of it has been necrotic, there may still be cancer cells surviving, timely surgical resection should be actively pursued, so that the patient can have the chance of radical treatment. TACE after radical resection of hepatocellular carcinoma can further remove the possible residual hepatocellular carcinoma cells in the liver and reduce the recurrence rate at the peak of recurrence. However, TACE has limited efficacy against disseminated satellite foci and portal vein thrombus, and it is more difficult to control distant metastasis of the foci and cannot block the occurrence of hepatocellular carcinoma. In order to achieve long-term prevention and treatment, it needs to be applied in combination with other treatments, with a view to fully mobilizing the biological anti-tumor mechanism of the organism after hepatic cancer resection, destroying the residual tumor cells, and further blocking the recurrence of hepatocellular carcinoma. For cases with residual cancer after palliative resection or recurrence after radical resection that can no longer be resected, TACE is still one of the preferred treatments.